Prolonged exposure to high levels of glucose and fatty acid (FFA) can induce tissue damage commonly referred to as glucolipotoxicity and is particularly harmful to pancreatic β-cells. Glucolipotoxicity-mediated β-cell failure is a critical causal factor in the late stages of diabetes, which suggests that mechanisms that prevent or reverse β-cell death may play a critical role in the treatment of the disease. Transcription factor PDX1 was recently reported to play a key role in maintaining β-cell function and survival, and glucolipotoxicity can activate mammalian sterile 20-like kinase 1 (Mst1), which, in turn, stimulates PDX1 degradation and causes dysfunction and apoptosis of β-cells. Interestingly, previous research has demonstrated that increased glucagon-like peptide-1 (GLP-1) signalling effectively protects β cells from glucolipotoxicity-induced apoptosis. Unfortunately, few studies have examined the related mechanism in detail, especially the role in Mst1 and PDX1 regulation. In the present study, we investigate the toxic effect of high glucose and FFA levels on rat pancreatic RINm5F β-cells and demonstrate that the GLP-1 analogue liraglutide restores the expression of PDX1 by inactivating Mst1, thus ameliorating β-cell impairments.
resistance and results in constantly high blood sugar levels. 5 Thus, hyperglycaemia seems to work synergistically with hyperlipidemia via a process referred to as glucolipotoxicity, which contributes to various cellular dysfunctions, including endoplasmic reticulum (ER) stress, oxidative stress, mitochondrial dysfunction and chronic low-grade inflammation. 6 Evidence has emerged that elevated serum FFA is implicated in stimulating cell dysfunction or cell death events, such as insulin resistance in skeletal muscle cells, fatty liver and steatosis in hepatocytes, and dysregulated insulin secretion and apoptosis in β-cells. 7 Although some studies demonstrate that lipotoxicity-induced apoptosis is a specific effect of saturated FFA, unsaturated FFA is also toxic in an alternative pathway, which suggests that both saturated and unsaturated FFA markedly differ in their contributions to lipotoxicity. 8 Therefore, the combination of both types of FFAs may best reflect the physiological or pathological situation under glucolipotoxicity. 9 Research has indicated that β-cells are particularly sensitive to glucolipotoxicity. 10 In fact, pancreatic β-cell dysfunction and death are two core features of the late stages of T2D. 11 In diabetics, β-cells secrete larger-than-normal amounts of insulin to overcome insulin resistance, causing overwork and overproduction of insulin for extended periods of time. Glucolipotoxicity also damages β-cells, leading to little or no insulin production in a vicious cycle that ultimately promotes cell dysfunction and death. 12 Thus, glucolipotoxicitymediated β-cell loss is a critical causal factor of the late stages of diabetes. Although the exact mechanisms have not been delineated, studies have indicated that high glucose and FFA-induced metabolic stress appears to regulate β-cell identity and fate by perturbation of some specific transcription factors. 13 In particular, pancreatic duodenal homeobox 1 (PDX1) has been reported to play a key role in maintaining β-cell function and survival. 14 Decreased expression of PDX1
can be found in β-cells isolated from T2D patients, which suggests that PDX1 is important in islet compensation for glucolipotoxicity-induced insulin resistance. 15 Similarly, prolonged exposure of β-cells to high glucose and FFA levels has been demonstrated to stimulate PDX1 nuclear exclusion and degradation, resulting in decreased insulin gene transcription and cell survival. 13 On the contrary, recent studies reveal that administration of a glucagon-like peptide 1 (GLP-1) analogue, liraglutide, ameliorates the impairments to β-cells by upregulation of PDX1 in high-fat diet-induced diabetic mice. 16 Therefore, upregulation of PDX1 may prevent the progression of the glucolipotoxicity-induced β-cell dysfunction found in T2D. These previous findings highlight the importance of understanding how PDX1 is regulated.
Ardestani et al showed that mammalian sterile 20-like kinase 1 (Mst1) can stimulate ubiquitin-proteasome degradation of PDX1 and prohibit its function as a transcription factor in the nucleus. 17 This result indicates that regulation of Mst1 and PDX1 may be involved in liraglutide-mediated β-cell protection. However, few studies have examined this mechanism in detail. Therefore, in the present study,
we investigate the effect of high glucose and FFA treatment on rat 
| ELISA to determine insulin levels
Cells were seeded overnight in 6-well plates and treated as indicated. Insulin levels in culture medium were quantified using an insulin rat ELISA kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. 
| Immunocytochemistry
After treatment, cells were fixed with 2% buffered paraformaldehyde, permeabilized in 0.25% Triton X-100 (Sigma-Aldrich) for 5 minutes at 4°C, and then incubated with anti-αSyn primary antibody.
Slides were incubated with an FITC-labeled second antibody (Santa Cruz) in accordance with the origin of the primary antibody. Cells were stained with 1 μg/mL AO for 15 minutes and then washed with RPMI-1640 medium. Thereafter, images were acquired by using a fluorescence microscope (DP80/BX53; Olympus) and cellSense V 1.9 digital imaging software. 
| Statistical analysis
All data are presented as means ± standard error of the mean. The statistical significance of differences between compared groups was determined through one-way analysis of variance following Dunnett's posthoc test for multiple comparisons with SPSS Statistics version 22.0 software (SPSS Inc., Chicago, IL, USA), as well as the two-tailed Student's t test. A probability value of <0.05 or <0.01 was specified to indicate statistical significance, and significance levels of *P < 0.05 or **P < 0.01 were set depending on individual experiments.
3 | RESULTS
| Exposure of RINm5F β-cells to high glucose and FFA levels increases apoptosis
Elevated glucose and FFA levels in the circulation play a pivotal role in causing β-cell damage. To fit the actual physiological composition of FFA, we used two common saturated and unsaturated dietary lipids, ie PA and OA, to establish a high-FFA condition. Figure 1A shows the morphological change achieved by treating RINm5f β-cells To further elucidate whether high glucose + FFA treatment interferes with RINm5f β-cell function during insulin synthesis and secretion, we performed relative expression qPCR assays to measure the levels of proinsulin mRNA transcripts. As shown in Figure 2B , no significant changes were found in the expression of proinsulin mRNA in the high-glucose group compared with that in the control group.
However, high FFA significantly suppressed mRNA levels of proinsulin, and this inhibition was enhanced by co-treatment with high FFA. The amount of insulin in the medium was determined by ELISA, and results revealed that high glucose + FFA treatment strongly suppresses insulin secretion ( Figure 2C ).
To determine whether the observed glucolipotoxicity-mediated β-cell dysfunction is due to Mst1, we conducted knockdown experiments using Mst1 siRNA. As expected, our results showed a ) effectively restored nuclear PDX1 levels, which means the Mst1-suppressed PDX1 pathway may be blocked by liraglutide. Indeed, cytosol and nuclear fractions of western blotting confirmed that the nuclear fraction of endogenous PDX1 is significantly restored by liraglutide ( Figure 3B) . Furthermore, the results in Figure 3C show that liraglutide markedly up-regulates PDX1 protein levels in high glucose and high FFA-treated cells. Moreover, cleaved and activated Mst1 protein was reduced by liraglutide. This result was also confirmed through MTT assays, which showed that liraglutide effectively alleviates high glucose and high FFA-induced cytotoxicity (Figure 3D) . Liraglutide further reduced the cleavage of caspase 3 and PARP ( Figure 3E ), thus indicating that it can protect against glucolipotoxicity-induced β-cell apoptosis by restoring Mst1-suppressed PDX1 expression levels.
F I G U R E 2
High glucose and FFA causes RINm5f β-cell dysfunction through reduction of PDX1 expression. A, Immunoblotting revealed that the expression of PDX1 is clearly down-regulated when cells are treated with high glucose and FFA for 24 hours. Conversely, the level of cleaved Mst1 markedly increased in the high glucose and FFA groups. B, Real-time qPCR was used to measure proinsulin mRNA transcript levels. C, Treatment of cells with high glucose and high FFA for 24 h showed significantly decreased insulin secretion levels in the culture medium. D, High glucose and high FFA induced marked PDX1 reduction. However, knockdown of Mst1 by siRNA partially restored this inhibition. E, Cell viability was determined through MTT assay. Mst1 knockdown led to a significant restoration of cell survival. At least three independent experiments were performed, and values are presented as mean ± SEM. Significant differences were determined through multiple comparisons with Dunnett's posthoc test at *P < 0.05 and **P < 0.01 compared with the control groups ER stress-induced apoptosis plays a key role in PDX1-deficient β-cell during glucolipotoxicity. 20, 21 To determine whether liraglutide protects cells from ER stress-induced cell death events, we measured two ER stress downstream typical markers, including PKR-like endoplasmic reticulum kinase (PERK) and eukaryotic translation initiation factor 2α (eIF2α), which activates a signalling network called the unfolded protein response to trigger C/EBP homologous proteinmediated apoptosis. 22 As shown in Figure 3F , treatment with high glu- were collected from at least three independent experiments, and values are presented as mean ± SEM. Significant differences were determined through multiple comparisons with Dunnett's posthoc test at *P < 0.05 and **P < 0.01 compared with the control groups treated cells. Liraglutide attenuated these effects caused by glucolipotoxicity, thus suggesting that decreased ROS content by liraglutide may be responsible for protection against glucolipotoxicity-induced cellular senescence.
| Liraglutide restores glucolipotoxicity-impaired mitophagy and mitochondrial membrane potential
Glucolipotoxicity-induced ROS accumulation and oxidative damage is caused by dysfunctional mitochondria. 27 Thus, the role of liraglutide in preventing glucolipotoxicity-mediated impairment of mitochondrial membrane potential was also investigated in this work. As shown in Figure 5A , exposure of cells to high glucose + FFA resulted in an increase in green fluorescence, indicating a great loss of mitochondrial membrane potential. However, co-treatment with liraglutide reduced the effects of high glucose + FFA on mitochondrial membrane potential significantly, thus suggesting that liraglutide preserves mitochondrial function against glucolipotoxicity.
Proliferator-activated receptor gamma coactivator 1 α (PGC1α) has been reported to be a positive regulator of mitochondrial function and renewal. 28 Therefore, we investigated whether glucolipotoxicity down-regulates PGC1α expression. As shown Figure 5B , high glucose + FFA caused a marked decrease in the expression of PGC1α at 24 hours post-treatment, and this inhibition was effectively restored by co-treatment of liraglutide.
Activation of PGC1α a and AMPK has been shown to enhance mitochondrial function and biogenesis by facilitating mitophagy. 29 We therefore investigated whether inhibition of mitophagy by high glu- Many studies have demonstrated that long-term exposure of β-cells to high glucose and high FFA induces dysregulated insulin synthesis and secretion, eventually resulting in apoptosis. Thus, identification of the underlying mechanisms by which glucolipotoxicity contributes to β-cell dysfunction and death is critical to develop novel therapeutic strategies aimed at delaying or preventing β-cell exhaustion. Although the exact mechanism involved in β-cell glucolipotoxicity has yet to be elucidated, several hypotheses have been proposed, including mitochondrial dysfunction, oxidative stress, ER stress and islet inflammation. 23 However, the specific apoptotic signalling pathways involved in these mechanisms have not been comprehensively studied. Mitophagy is the selective degradation of mitochondria by autophagy and has been the subject of intense research in biological processes ranging from cellular metabolism to senescence. Increased mitophagy is thought to accelerate mitochondrial turnover, which, in turn, appears to maintain mitochondrial function and quality. 36 In diabetes, dysfunctional mitochondria have been linked to increased levels of ROS accumulation, which ultimately underlies β-cell failure and apoptosis. 37 Moreover, mitochondrial dysfunction and oxidative stress are largely involved in cellular senescence, thus suggesting that protecting and improving mitochondrial function may be a useful strategy for treating some oxidative stress-associated diseases, including neurodegeneration, metabolic syndrome and diabetes. In our results, we demonstrated that, under glucolipotoxicity, liraglutide up-regulates the AMPK/LC3 autophagy pathway, which drives the turnover of dysfunctional mitochondria in β-cells. Interestingly, previous studies indicate that binding of GLP-1 to its β-cell receptor elevates PGC1α expression, which means activation of GLP-1 signalling may improve β-cell functions via enhanced mitochondrial performance. 38 Our findings revealed that co-treatment of liraglutide effectively restore glucolipotoxicity-induced PGC1α downregulation.
Recent evidence also suggests the diminished expression of PGC1α in humans with insulin resistance and diabetes. 39 As PGC1α is the master regulator of mitochondrial turnover, restoration of mitophagy by liraglutide can prevent glucolipotoxicity toxicity. 40 In the present study, we provide evidence of the ability of liraglutide to inhibit high glucose and high FFA-induced β-cell toxicity. This protective effect appears to be associated with Mst1 and PDX1-related regulation and mitophagy activation. To the best of our knowledge, our group
is the first to demonstrate the molecular mechanism of liraglutide against glucolipotoxicity-induced β-cell damage by the Mst1 and 
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